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Abstract
Background: BAP1 has been shown to be a target of both somatic alteration in high-risk ocular melanomas (OM) and
germline inactivation in a few individuals from cancer-prone families. These findings suggest that constitutional BAP1
changes may predispose individuals to metastatic OM and that familial permeation of deleterious alleles could delineate a
new cancer syndrome.
Design: To characterize BAP1’s contribution to melanoma risk, we sequenced BAP1 in a set of 100 patients with OM,
including 50 metastatic OM cases and 50 matched non-metastatic OM controls, and 200 individuals with cutaneous
melanoma (CM) including 7 CM patients from CM-OM families and 193 CM patients from CM-non-OM kindreds.
Results: Germline BAP1 mutations were detected in 4/50 patients with metastatic OM and 0/50 cases of non-metastatic OM
(8% vs. 0%, p=0.059). Since 2/4 of the BAP1 carriers reported a family history of CM, we analyzed 200 additional hereditary
CM patients and found mutations in 2/7 CM probands from CM-OM families and 1/193 probands from CM-non-OM kindreds
(29% vs. 0.52%, p=.003). Germline mutations co-segregated with both CM and OM phenotypes and were associated with
the presence of unique nevoid melanomas and highly atypical nevoid melanoma-like melanocytic proliferations (NEMMPs).
Interestingly, 7/14 germline variants identified to date reside in C-terminus suggesting that the BRCA1 binding domain is
important in cancer predisposition.
Conclusion: Germline BAP1 mutations are associated with a more aggressive OM phenotype and a recurrent phenotypic
complex of cutaneous/ocular melanoma, atypical melanocytic proliferations and other internal neoplasms (ie. COMMON
syndrome), which could be a useful clinical marker for constitutive BAP1 inactivation.
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Introduction
For ocular melanoma (OM), monosomy 3 is one of the most
powerful independent predictors of metastasis and negative
outcome [1]. Recently, somatic mutations of BAP1 (BRCA1
associated protein-1/ubiquitin carboxy-terminal hydrolase) were
identified in a large fraction of high-risk (ie. class 2 by expression
profiling) OM tumors which exhibited monosomy 3 [2].
Subsequently, five families with deleterious germline BAP1
mutations were also described including several kindreds with
both ocular and cutaneous melanoma (CM) [3,4,5]. These studies
suggest that germline BAP1 mutations may orchestrate a
metastatic OM program and that transmission of deleterious
alleles may engender a mixed CM-OM pedigree, which could
serve as a clinical marker of constitutive BAP1 loss. The context of
susceptibility includes CM patients who report a family history of
OM since CM is 40-fold more common than its ocular
counterpart (incidence: 20.4 vs. 0.51, www.seer.cancer.gov [6]).
We thus set out to determine if germline BAP1 mutations are more
prevalent among (i) OM patients with metastatic disease compared
to non-metastatic controls and (ii) CM-OM kindreds relative to
CM-non-OM families.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35295Figure 1. Cohorts and pedigrees. (A). Ocular melanoma and cutaneous melanoma cohorts used in this study. (B). Fam-562 pedigree and clinical
images of two nevoid melanoma-like melanocytic proliferations (NEMMPs) diagnosed in Fam729. (C). Fam-729 pedigree. One carrier had a Spitz
nevus, which has been reported to harbor somatic BAP1 mutations [4]. Abbreviations: M, mutation carrier; wt, wildtype germline sequence; Ob,
obligate carrier; OCMEL, ocular melanoma; MEL, cutaneous melanoma; NEMMPs, nevoid melanoma-like melanocytic proliferations; BR, breast cancer;
CHL, cholangiocarcinoma; LG, lung cancer; KID, kidney cancer; UNP, melanoma of unknown primary site; CNS, central nervous system tumor; LK,
BAP1 Ocular Cutaneous Melanoma
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35295We sequenced and identified BAP1 mutations in 4/50 OM
cases with metastases vs. 0/50 OM controls without metastases
(8% vs. 0%, p=.059) and 2/7 CM patients from mixed CM-OM
families vs. 1/193 CM probands from non-OM families (29% vs.
0.52%, p=.003). Subsequent analysis of 31 additional members
from the 2 CM-OM families revealed that all 4 affected members
with CM were in fact BAP1 mutation carriers. In aggregate, there
were 6 distinct novel germline BAP1 variants out of 300 melanoma
patients analyzed. Interestingly, half (7/14) of the known germline
mutations to date localized to the C-terminus of BAP1 (close to
BRCA1 binding region) suggesting that this may represent the
critical domain for heritable cancer risk.
Materials and Methods
Patients
This study was performed in accordance with a protocol
approved by the Institutional Review Boards (IRB) at the
Massachusetts General Hospital (MGH) and the Massachusetts
Eye and Ear Infirmary (MEEI).
Ocular melanoma cohort (MEEI). All blood samples were
obtained between 1992 and 2006. From this time period, we
identified 50 patients who donated blood to our melanoma registry
who developed metastasis from OM. These ‘‘cases’’ had at least
one sample, obtained at the time of diagnosis, available for
analysis. We also included 50 OM patients who had no evidence
of metastasis. These ‘‘controls’’ were matched on age at diagnosis
(65 years), gender, largest tumor diameter (LTD, 63 mm), and
ciliary body involvement by the tumor. Selected controls also had
follow-up times at least as long as the cases to which they were
matched in order to minimize misclassification.
Genetically enriched cutaneous melanoma cohort
(MGH). Between April 2001 and June 2011, all in-situ and
invasive cutaneous melanoma patients evaluated at the
Massachusetts General Hospital Pigmented Lesion Center (see
details [7,8]) were screened for hereditary risk as defined by (i) one
or more 1st degree relatives with CM or OM or (ii) two or more
affected relatives with CM or OM on one side of family or (iii)
three or more primary melanomas in the absence of a family
history. The presence and number of melanomas for probands
were confirmed via pathology reports for all but a small number of
cases (,10%, data not shown). Per our IRB-approved protocol,
we only pursued medical record confirmation of reported family
history if relatives provided prior consent to participate in our
study. Details of both cohorts are listed in Table S1.
Mutational Analysis
DNA from peripheral blood leukocytes was extracted with the
Qiagen DNEasy Kit (Qiagen; Valencia, CA). BAP1 was analyzed
using the primer sequences outlined in Table S2. For tumor
analysis, BRAF exon 15 was sequenced using 59 TCA TAA TGC
TTG CTC TGA TAG GA 39 (forward) and 59GGC CAA AAA
TTT AAT AAT CAG TGG A 39 (reverse) while GNAQ was
sequenced as described [9]. The putative amplicons were size
confirmed by gel electrophoresis, treated with ExoSAP-IT
(Affymetrix/USB Corporation, Cleveland, OH) and submitted
to the institutional sequencing core.
Results
Since BAP1 mutations are known to be more prevalent in high-
risk, class 2 OMs, we set out to determine if germline BAP1
mutations could be instructive of a metastatic phenotype by
comparing the rates of BAP1 alterations among 50 metastatic OM
cases and 50 non-metastatic OM controls matched for gender,
age, largest tumor diameter (LTD) and ciliary body involvement
(Figure 1A; Table S1). The median follow-up duration was 9.2
years for the non-metastatic controls vs. 4.2 yrs for metastatic the
cases; thus, misclassification was minimized.
Germline BAP1 mutations were detected in 4/50 of the
metastatic cases (Table 1; #3123: p.Glu611Argfs*5, #2734:
p.Ala634Glyfs*5, #3101: p.Lys659X and #3382: p.Arg385X)
and in 0/50 of the non-metastatic controls (8% vs. 0%, p=.059,
Fisher Exact test). All 4 BAP1 mutation carriers developed liver
metastases and died of their disease. Interestingly, 2 of the 4
metastatic OM patients reported a family history of cutaneous
melanoma though neither carrier had cutaneous melanocytic
tumors themselves. These findings suggest that BAP1 alterations
may be associated with a more aggressive OM phenotype.
Moreover, it supports our initial supposition that germline
transmission leads to both CM and OM predisposition, as found
in our patients and as previously reported [3,4].
To test the possibility that germline BAP1 inactivation is
preferentially linked to a CM-OM familial phenotype, we
undertook the complementary strategy and screened 200 hered-
itary CM individuals for a family history of OM. From this
collection, there were 7 CM-OM (7/200=3.5%) and 193 (193/
200=96.5%) CM-non-OM kindreds (Figure 1A, Table S1); thus,
mixed CM-OM pedigrees were expectedly uncommon. Germline
BAP1 mutations were detected in 2/7 probands (#562: p.As-
p236Glyfs*7 and #729: p.Arg385X) from CM-OM families and
1/193 probands (#714: p.Arg60X) from CM-non-OM kindreds
(29% vs. 0.52%; p=.003, Fisher Exact Test). Record tracking
afterwards revealed that both carriers of the p.Arg385X mutation
(#3382: OM and #729: CM) were indeed members of a single
kindred (Fam-729) but were evaluated at MGH and MEEI
separately. Proband #714 (p.Arg60X) had only a single sibling
who died from metastatic melanoma at age 16 (primary site
unknown) and a mother who died from lung cancer when he was
young. None of the CM-OM families had germline CDKN2A, ARF
or CDK4 mutations (data not shown).
Additional genetic material was available in two of the CM-OM
kindreds for segregation analysis (Fam-562, 7 total individuals;
Fam-729, 26 total individuals). As shown in Figure 1, BAP1
mutations were identified in all patients with a history of CM, OM
or highly atypical melanocytic tumors (see below). Overall, 4/7
members of Fam-562 were carriers of the p.Asp236Glyfs*7
mutation while 9/26 members of Fam-719 harbored the
p.Arg385X alteration.
The cutaneous phenotype associated with BAP1 alterations was
quite striking. Carriers from three BAP1-mutated families
developed ‘‘nevoid’’ melanomas (#714; Fam-562 II-4 and Fam-
729 I-1, Figure 1)- an uncommon subtype of CM. We had the
opportunity to follow one kindred (Fam-562) over time and
examined their skin tumors in detail. In this family, the
p.Asp236Glyfs*7 carriers developed diagnostic tumors that were
distinctively semi-translucent, orange-red oval-shaped plaques or
leukemia. Crosses indicate CM with a nevoid pattern. The numbers next to the ‘‘MEL’’ indicate ages of diagnosis. For the sake of confidentiality, the
pedigrees have been masked for some non-affected individuals and siblings. Nonessential gender information has also been disguised by a diamond; the
number of individuals collapsed into the diamond is indicated.
doi:10.1371/journal.pone.0035295.g001
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35295dome-shaped papules (Figure 1B) rather than the irregularly
pigmented plaques and nodules more commonly associated with
dysplastic nevi and cutaneous melanomas. However, the banal
clinical morphology stood in sharp contrast to the severely atypical
histopathology, which harbored cytological attributes reminiscent
of a nevoid melanoma. A prominent feature seen in these lesions
was the presence of dermal expansile nodule or nodules composed
of atypical melanocytes and overall features of nevic cells but with
irregular and hyperchromatic nuclei. They also showed rare
mitotic activity and focal increases in Ki67 staining (Figures 2A-F).
Despite the high degree of atypia, classic features of melanoma
such as invasive epithelioid malignant-appearing cells at the base
of the tumor and pagetoid spread were not observed. In many
cases, the atypical cytological and architectural features fell short
of frank malignancy though these lesions clearly lie within the
spectrum of nevoid melanomas. We designate these atypical
tumors as NEvoid Melanoma-like Melanocytic Proliferations
(NEMMPs), which may be related to the Spitz-like tumors
reported earlier [4]. Similar histologic features were also evident
in non-melanoma tumors removed from p.Arg60X and
p.Arg385X mutation carriers. Thus, the spectrum of tumorigen-
esis from highly atypical NEMMPs to nevoid melanomas appears
to be a unique property of BAP1-mediated cutaneous carcinogen-
esis.
Molecular analysis of 7 available cutaneous tumor specimens
from Fam-562 (1 superficial spreading melanoma, 1 nevoid
melanoma and 5 NEMMPs) revealed loss-of-heterozygosity
(Figure 2G) in the nevoid melanoma and a second inactivating
somatic mutation (p.Ser123Lysfs*3; Figure 2H) in one of the
NEMMPs. In addition, 4 of 7 lesions harbored somatic BRAF
V600E
mutations while none had GNAQ
R183/Q209 alterations (data not
shown). The molecular data support a two-hit event at this locus
and suggest that the nevoid melanomas and NEMMPs are more
oncogenically aligned with commonly-acquired melanomas and
moles rather than blue nevi.
As reported in the literature, the BAP1 families appear to be at
risk for other internal malignancies (Table 1). Among documented
carriers, there were two confirmed lung adenocarcinomas
(p.Asp236Glyfs*7 and p.Arg385X), one renal cell carcinoma
(p.Asp236Glyfs*7), one DCIS (p.Arg385X) and one cholangio-
carcinoma (p.Arg385X carrier); unfortunately, genetic material
from these other tumors was not available for further analysis.
BAP1 carriers also reported additional kidney, bladder, uterine,
breast and bone cancers (Table 1) though these could not be
confirmed by pathology since the probands were deceased. There
were neither cases of mesotheliomas nor meningiomas.
Discussion
In this study, we performed a comprehensive screen of BAP1 in
melanoma patients to date and our findings point to an important
role for BAP1 in melanoma predisposition. First, BAP1 mutations
occur with greater frequency among metastatic OM cases
compared to non-metastatic OM controls (8% vs. 0%, p=.059).
Therefore, germline BAP1 inactivation appears to contribute to
metastatic risk in a small, but significant, proportion of ocular
melanoma cases. Biologically, this is consistent with the increased
rate of somatic BAP1 mutations in high-risk OM tumors over low-
risk ones (84% vs. 4% [2]).
The higher rate of BAP1 alterations among CM patients from
mixed CM-OM lineages compared to other hereditary melanoma
patients (29% vs. 0.52%; p=.003). Observations from our
kindreds, along with those already published [3,4,5], anchor
BAP1 to a phenotypic complex defined by cutaneous and ocular
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35295melanomas, characteristic melanocytic proliferations and other
internal neoplasms and thus we propose the designation
‘‘COMMON’’ syndrome, or complex, as a unifying entity.
Beyond familial susceptibility, the observed cutaneous histogenesis
is rather unique in its formation of an uncommon pattern of
nevoid proliferations ranging from frank melanomas to highly
atypical dermal expansile nodules (ie. NEMMPs)- a similar entity
was described in another recent publication [4]. With case #714,
the nevoid CM and NEMMPs were the only clues to the BAP1
genotype since there were no reports of OM in the family.
Interestingly, BAP1 suppression in uveal melanoma cells led to a
profound shift from spindled bipolar cells to more rounded
epithelioid cells [2]- a cellular phenotype consistent with the
observed histopathology. Taken together, the cutaneous melano-
cytic tumors are among the most characteristic aspects of the
COMMON syndrome and may represent a defining lesion in the
future.
When germline mutations from this study are combined with
those previously published (Figure 3), there is the suggestion of
clustering at the C-terminus of BAP1; this is the region known to
interact with BRCA1. This raises the possibility that the BAP1-
BRCA1 interface is important for tumor suppression though
melanoma is not usually considered a canonical tumor within
the BRCA1 cancer spectrum and BRCA1 has not been shown to
be significantly mutated in either CM or OM [10]. An
alternative explanation for the C-terminus clustering is that
retention of N-terminus BAP1 function is in fact essential for
survival. Since several CM-OM families lack BAP1 mutations,
Figure 2. Histologic and molecular analyses of tumors from Fam-562. (A)–(F): Histology of 2 distinct NEMMPs. (A) Scanning view of the first
lesion showing two expansile dermal nodules (H&E, 26,) with a (B) benign nevoid appearance (H&E, 106). (C) Atypical cytological features including
nuclear pleomorphism and prominent nucleoli and a dermal mitotic figure (arrow) (H&E, 406) along with focal increases in Ki67 staining (inset). (D)I n
the second lesion, there is an expansile dermal proliferation (H&E, 46). (E) Detail of a field populated by dermal nevic cells with bland nuclear features
(H&E,206). (F) A proliferative area showing marked nuclear atypia and hyperchromasia along with elevated Ki 67 staining (inset). Biallelic inactivation
of BAP1 in two tumors through (G) loss of the wildtype allele in a nevoid melanoma (ie. LOH; arrow) or (H) a secondary mutation (p.Ser123Lysfs*3) in
a NEMMP that did not exhibit LOH.
doi:10.1371/journal.pone.0035295.g002
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35295other components of this pathway may be targeted- a hypothesis
that is currently under investigation. Regardless, the low rate of
somatic BAP1 alterations itself in sporadic CM [4] along with
the rarity of the characteristic NEMMP and nevoid melanoma
lesions in the general melanoma population suggest that BAP1
m u t a g e n e s i si sl i n k e dt oar e s t r icted carcinogenic pathway in
melanocytes.
It is also clear that other non-melanocytic tumors may develop
within this COMMON context though the full spectrum of
susceptible malignancies is still unknown. Among our families,
there were three individuals with lung cancer (not mesothelio-
mas), two of whom carried documented BAP1 mutations. In
recent findings, BAP1 has also emerged as both somatic and
germline targets in mesotheliomas [5,11] though mesotheliomas
were not reported by any of our carriers. Interestingly, patients
with OM and mesotheliomas have been described as early as
1972 [12]. Overall, CMs, OMs and mesotheliomas appear to be
sentinel cancers within the COMMON spectrum although other
cancers are likely to be implicated as more mutations are
described.
Functionally, BAP1 is a nuclear deubiquitinating enzyme that
has tumor suppressive activities in conjunction with and also
independent of BRCA1 [13]. BAP1 has been found to be
important in cell cycle regulation and was shown to partner with
the transcriptional regulator host cell factor 1 (HCF-1) [14]. With
BAP1 suppression in a uveal melanoma line [2], there were
dramatic changes in the levels of genes known to regulate pigment
cell development (eg. EDNRB, KIT, SOX10) though the precise
mechanism of BAP1 action has yet to be elucidated. Although the
directs targets of BAP1 have not been fully elucidated, other
melanocyte-specific tumor proteins, such as MITF, have been
shown to be regulated by another deubiquitinating enzyme,
named ubiquitin-specific protease 13 (USP13) [15]. Furthermore,
a deleterious mutation in an yeast deubiquitinating enzyme, Ubp6,
has been linked to aneuploidy tolerance [16]. Taken together, the
precise targets that drive melanoma progression in the face of
BAP1 loss are not known though widespread effects in many
diverse pathways are likely given the role of ubiquitination in the
maintenance of genetic homeostasis.
In conclusion, our evidence suggests that germline BAP1
inactivation is preferentially associated with metastatic OM and
hereditary CM-OM in a small but significant proportion of cases.
The unique clinicopathologic features of the COMMON complex
await further clarification with the description of additional
families and a more refined genotype-phenotype correlation.
Looking ahead, one could envision using COMMON features (eg.
nevoid melanomas and NEMMPs) in order to clinically identify
potential BAP1 mutation carriers, who may benefit from targeted
screening for high-risk ocular melanomas.
Figure 3. Distribution of BAP1 mutations. Inactivating germline mutations identified in this study are indicated by the red arrows. Reported
somatic missense mutations (blue bars) and indels (blue arrows) from ocular melanoma specimens (COSMIC database; http://www.sanger.ac.uk/
genetics/CGP/cosmic/) and germline variants (blue lines) from other families are also shown. Half of the germline variants occur in the terminal 150
amino acids while the somatic changes are more scattered.
doi:10.1371/journal.pone.0035295.g003
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